Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection

Stock Track

2025/08/11

Shares of Amphastar Pharmaceuticals (AMPH) surged 8.81% in pre-market trading on Monday following the announcement that the U.S. Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP. This generic drug is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.

The FDA approval covers single-dose vials in dosages of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, highlighting the company's commitment to developing complex generics and maintaining high regulatory standards. The company plans to launch the product in the third quarter of 2025.

This approval positions Amphastar to enter a lucrative market. The comparable product, Venofer®, has reported sales of approximately $513 million over the past year. Investors are likely optimistic about the potential revenue boost this new product could bring to Amphastar, driving the significant pre-market stock price increase. The company's ability to successfully navigate the FDA approval process for complex generics may also be viewed positively by the market, potentially indicating future growth opportunities.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1140567448"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140567448\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140567448?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140567448","market":"nz","top_or_hot":-1,"title":"Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection","media":"Stock Track","content":"<p>Shares of Amphastar Pharmaceuticals (AMPH) surged 8.81% in pre-market trading on Monday following the announcement that the U.S. Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP. This generic drug is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.</p>\n\n<p>The FDA approval covers single-dose vials in dosages of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, highlighting the company's commitment to developing complex generics and maintaining high regulatory standards. The company plans to launch the product in the third quarter of 2025.</p>\n\n<p>This approval positions Amphastar to enter a lucrative market. The comparable product, Venofer®, has reported sales of approximately $513 million over the past year. Investors are likely optimistic about the potential revenue boost this new product could bring to Amphastar, driving the significant pre-market stock price increase. The company's ability to successfully navigate the FDA approval process for complex generics may also be viewed positively by the market, potentially indicating future growth opportunities.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Amphastar Pharmaceuticals Soars 8.81% Pre-market on FDA Approval for Generic Iron Sucrose Injection\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-08-11 20:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Shares of Amphastar Pharmaceuticals (AMPH) surged 8.81% in pre-market trading on Monday following the announcement that the U.S. Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP. This generic drug is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.</p>\n\n<p>The FDA approval covers single-dose vials in dosages of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, highlighting the company's commitment to developing complex generics and maintaining high regulatory standards. The company plans to launch the product in the third quarter of 2025.</p>\n\n<p>This approval positions Amphastar to enter a lucrative market. The comparable product, Venofer®, has reported sales of approximately $513 million over the past year. Investors are likely optimistic about the potential revenue boost this new product could bring to Amphastar, driving the significant pre-market stock price increase. The company's ability to successfully navigate the FDA approval process for complex generics may also be viewed positively by the market, potentially indicating future growth opportunities.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMPH","symbol_name":"Amphastar Pharmaceuticals","start_time":0,"source_url":"","article_id":"1140567448","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140567448","pubTimestamp":1754915080,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Amphastar Pharmaceuticals (AMPH) surged 8.81% in pre-market trading on Monday following the announcement that the U.S. Food and Drug Administration (FDA) has approved the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMPH":"Amphastar Pharmaceuticals"},"translate_title":"股票追踪|FDA批准仿制药蔗糖铁注射液Amphastar Pharmaceuticals盘前飙升8.81%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMPH":1},"content_text":"Shares of Amphastar Pharmaceuticals (AMPH) surged 8.81% in pre-market trading on Monday following the announcement that the U.S. Food and Drug Administration (FDA) has approved the company's Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP. This generic drug is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease.\nThe FDA approval covers single-dose vials in dosages of 50mg/2.5mL, 100mg/5mL, and 200mg/10mL. Dr. Jack Zhang, Amphastar's President and CEO, expressed enthusiasm for the approval, highlighting the company's commitment to developing complex generics and maintaining high regulatory standards. The company plans to launch the product in the third quarter of 2025.\nThis approval positions Amphastar to enter a lucrative market. The comparable product, Venofer®, has reported sales of approximately $513 million over the past year. Investors are likely optimistic about the potential revenue boost this new product could bring to Amphastar, driving the significant pre-market stock price increase. The company's ability to successfully navigate the FDA approval process for complex generics may also be viewed positively by the market, potentially indicating future growth opportunities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}